PRESS-RELEASE ·Filed Oct 22, 2026
Press release · Earnings
Price Chart
Loading chart...
Executive Summary
BridgeBio Pharma, Inc. announced it will report its Q3 2026 results on October 29, 2026.
Key Facts
- BridgeBio Pharma, Inc. announced it will report its Q3 2026 results on October 29, 2026.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3386214 |
33 reports for BBIO
70% Hit rate @ T+20 Went positive at some point 11 of 13 best @ T+60▲ +26.76%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G | $68.25 | awaiting T+20 | awaiting T+20 | $69.37 (+1.64%) |
Oct 22, 2026 5d ago | Press Release | $68.12 | awaiting T+20 | awaiting T+20 | $69.37 (+1.84%) |
Oct 13, 2026 14d ago | 8-K | $63.30 | awaiting T+20 | awaiting T+20 | $69.37 (+9.59%) |
Oct 6, 2026 21d ago | Press Release | $66.96 | awaiting T+20 | awaiting T+20 | $69.37 (+3.60%) |
Oct 5, 2026 22d ago | Press Release | $66.96 | awaiting T+20 | awaiting T+20 | $69.37 (+3.60%) |
Oct 5, 2026 22d ago | Press Release | $66.14 | awaiting T+20 | awaiting T+20 | $69.37 (+4.88%) |
Sep 18, 2026 5w ago | Press Release | $66.58 $67.94 | ▲ +2.04% | ▲ +2.95% | $69.37 (+4.19%) |
Aug 31, 2026 8w ago | 8-K | $76.59 $65.97 | ▼ −13.87% | ▼ −13.68% | $69.37 (−9.43%) |
Aug 26, 2026 8w ago | Press Release | $79.37 $66.28 | ▼ −16.49% | ▼ −16.72% | $69.37 (−12.60%) |
Aug 22, 2026 9w ago | Institutional Cluster | $81.07 $69.23 | ▼ −14.60% | ▼ −15.92% | $69.37 (−14.43%) |
Showing 10 of 33
US Market Status
Market Closed · Opens in 5h 56m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers